Robert C. Goeltz II
2018 - Unity Biotechnology
In 2018, Robert C. Goeltz II earned a total compensation of $908K as Chief Financial Officer at Unity Biotechnology.
Compensation breakdown
| Non-Equity Incentive Plan | $142,325 |
|---|---|
| Option Awards | $392,653 |
| Salary | $373,068 |
| Total | $908,046 |
Goeltz received $392.7K in option awards, accounting for 43% of the total pay in 2018.
Goeltz also received $142.3K in non-equity incentive plan and $373.1K in salary.
Rankings
In 2018, Robert C. Goeltz II's compensation ranked 9,660th out of 14,244 executives tracked by ExecPay. In other words, Goeltz earned more than 32.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 9,660 out of 14,244 | 32nd |
Division Manufacturing | 3,888 out of 5,765 | 33rd |
Major group Chemicals And Allied Products | 1,465 out of 2,128 | 31st |
Industry group Drugs | 1,235 out of 1,817 | 32nd |
Industry Pharmaceutical Preparations | 950 out of 1,391 | 32nd |
Source: SEC filing on April 24, 2020.
Goeltz's colleagues
We found three more compensation records of executives who worked with Robert C. Goeltz II at Unity Biotechnology in 2018.